Rapid-eye-movement (REM) sleep suppression has been proposed as a mechanism of action of antidepressant medications (Vogel et al. 1972; Vogel 1983) . In support of this, Kupfer et al. (1981) have shown that a drug-in duced increase in REM latency predicted antidepressant response, and under some circumstances, drug-induced REM suppression predicted symptom improvement (Kupfer et al. 1981) . With the exception of trimipramine, a sedating tricyclic (Ware et al. 1989) , most antidepres sant drugs of this class, and also monoamine oxidase inhibitors (Kay et al. 1976) , inhibit REM sleep (Vogel et al. 1990 ). Nefazodone, a phenylpiperazine agent, is a serotonin-2 (5-HT2) receptor antagonist and a selec tive 5-HT reuptake inhibitor (Eison et al. 1990) . It is chemically distinct from tricyclic antidepressants and from frrst-and second-generation 5-HT reuptake inhib-(REM) latency and it did not suppress REM sleep. In fact, a trend toward increased REM in the second REM period was observed, although decreased REM in the third REM period was also noted.
In summary, nefawdone, an effective antidepressant, decreases arousals and wakefulness during sleep and reduces light non-REM sleep. This agent does not appear to suppress REM sleep or prolong REM latency in patients who respond to treatment. [Neuropsychopharmacology 10:123-127, 1994J itors. Recent clinical trials indicate that nefazodone is an effective antidepressant drug (Feighner et al. 1989; Fontaine et al. 1991 ) that may increase REM sleep in normal subjects (Ware et al. 1991; Sharpley et al. 1992) .
Major depression has been linked to abnormalities of 5-HT neurotransmission (Rush et al. 1991) . Research has shown that administration of agents that block syn thesis of 5-HT as well as ingestion of compounds that deplete tryptophan results in increases in depressive symptoms (Delgado et al. 1991) . Inasmuch as 5-HT is implicated in the onset of sleep (Jones 1991) and per haps in the regulation of both REM and non-REM (NREM) sleep (Siegel 1990 ), nefazodone and other com pounds that alter 5-HT metabolism might be expected to alter sleep architecture in patients suffering from ma jor depression. The purpose of this pilot study was to investigate the effects of nefazodone on sleep in depression.
METHODS

Subjects
Subjects, 18 years of age or older, who met DSM-III-R criteria for nonpsychotic, major depression, but who were otherwise physically healthy, and who provided written informed consent were included. Excluded were those individuals currently engaged in shiftwork and those with independent sleep disorders (e.g., nar colepsy, apnea, bruxism, myoclonus) as established by history or polysomnogram. In addition, other current axis I disorders, current medical conditions, or psy choactive substance use within 12 months prior to base line measurements caused subjects to be excluded. Women were excluded if they were pregnant or lactat ing or were not using an adequate method of con traception.
Diagnoses were made based on the structured clin ical interview for DSM-III-R (Spitzer et al. 1986) . A 17-item Hamilton Depression Rating Scale (HDRS) (Hamil ton 1960) was also used, and a detailed personal and family history was obtained at the time of clinical inter view. Ten outpatients with major depression (fIve men, fIve women), averaging 42.9 (SO = 9.9) years of age, participated in the study. All patients were symptom atic (HDRS = 20.7; SO = 4.3) at the time of study and had an average onset of depression at age 27.7 (SO = 11.7) years. Seven of the 10 patients had recurrent ma jor depression (three patients had more than fIve epi sodes), whereas three were experiencing a fIrst episode of depression. One patient was clearly endogenous, fIve were probable endogenous, and four were nonen doge no us by Research Diagnostic Criteria (Spitzer et al. 1986 ). None had melancholic features by DSM-III-R. All patients knew they would be treated with nefaz odone.
Procedure
Each subject maintained individualized, regular bed and rise times for at least the 5 days prior to polysom nographic (PSG) study, as assessed by home diary. The subjects spent two consecutive baseline nights in the University of Texas Southwestern Medical Center Sleep Study Unit. Patients returned to the laboratory for 2 additional nights after no less than 4 weeks of nefazo done treatment. Electroencephalographic (EEG) data were collected from left (C3) and right (C4) central elec trodes with a linked-ear reference. Monopolar, left and right electrooculograms, and bipolar chin-cheek elec tromyograms were also recorded. A full electrode mon tage, used on the fIrst night in the sleep laboratory, in cluded leg, chest, and abdomen leads, and a nasal-oral thermistor to rule out independent sleep disorders. All electrophysiologic signals were recorded on GRASS P-511 AC amplifIers and displayed on a paperless poly graph system. An amplifIer sensitivity of 5 was used for EEG (50 J.1V, 0.5-second duration calibration), with half-amp low-and high-bandpass fIlters set at 0.3 and 30 Hz. A 60-Hz notch fIlter attenuated electrical noise. Interelectrode impedances were maintained below 2
Khom. AmplifIers were calibrated before and after each night's sleep. As is standard procedure in our labora tory, EEG amplifIers were counterbalanced between the hemispheres, across subjects, and between nights to rule out amplifIer artifact as a contributing source to interhemispheric differences (Armitage et al. 1989 ) rou tinely evaluated in computer-analyzed EEG frequen cies, but not reported here.
Dosing Procedure
All patients began treatment by taking 100 mg/day of nefazodone at bedtime for 3 days, followed by 100 mg bid. Dose was then increased to 100 mg in the morning and 200 mg in the evening for 3 additional days. By the end of the 2nd week of treatment, the dose was 200 mg in the morning and 200 mg in the evening and was in creased to a total daily dose of 500 to 600 mg/ day if deemed necessary by the attending physician. Patients received an average dose of 520 mg/day (SO = 79) of nefazodone (range 400 to 600 mg/day) during the 7 days preceding the sleep study. The average length of drug treatment following stabilization of dose was 48.7 (SO = 7.1) days. The mean HDRS score at the time of the sec ond sleep study was 8.2 (SO = 3.2), more than a 60% reduction from the pretreatment scores.
Sleep EEG records were scored from C3 according to standard Rechtschaff en and Kales (1968) criteria by technicians trained at better than 90% agreement on an epoch-by-epoch basis. A number of sleep variables were derived from the sleep-stage score data. Total time in bed was computed as the total time from lights-out to wake-up time. Sleep onset latency was defIned as the time elapsed before the fIrst epoch of sleep in a 10-minute segment containing no more than 2 minutes of wakefulness or the time in minutes to the fIrst half minute of REM sleep, whichever was sooner (Rush et al. 1989) . Total sleep period (TSP) was defIned as the length of time from sleep onset to wake up. Sleep efficiency was computed as the ratio of all sleep time to total time in bed. Rapid-eye-movement latency was equal to the number of minutes, including wake and movement time, from sleep onset to the fIrst epoch of REM sleep (irrespective of REM period duration). The length or duration of REM period was defIned as the fIrst to the last half-minute REM epoch, in an interval of REM sleep unbroken by more than 30 minutes of NREM or awake and movement time (REMDUR1, REMDUR2, and REMDUR3). The number of minutes of net REM in each REM period was also computed (REMIN1, REMIN2, and REMIN3). Minutes and per centages of each sleep stage and of awake and move ment time were computed in relation to TSP. Arousals were defIned as the total number of awake episodes of 0.5 minutes or longer duration in TSP.
Eight patients remitted with treatment (HDRS � 10). The remaining two patients also responded to treatment as evidenced by greater than 50% reduction in the HDRS scores (fmal HDRS scores: 11 and 13). All 10 Ss were included in the statistical analyses. The data were coded for night-in-study and treatment level (base line [drug-free] T1 versus [on nefazodone] T2) and repeated-measures analyses of variance were com puted. Table 1 presents the means and standard deviations of all sleep measures by treatment condition. Although the convention is to report signmcance at a = .05, this study is based on a small sample size. In actuality, effect sizes can be quite large but can fail to reach signmcance due to low statistical power. As such, trends are indi cated at probabilities below .10 (Stevens 1986). As no ev idence of a statistically signmcant night effect was found, the data were averaged and analyses were recomputed based on the means of nights 1 and 2. To be compatible with existing published data, both minutes and percentages of each sleep stage are presented. Variables that showed signmcant treatment effects or trends are identifIed by asterisks.
Several sleep parameters showed signibcant changes with drug treatment. Analysis of variance summaries are presented in Table 2 . Decreases in the number of arousals, in stage 1 sleep percent, and percent and 
DISCUSSION
In this acute-phase, open-trial study of non psychotic outpatients with major depression during treatment with nefazodone, there was a signifIcant decrease in wakefulness and light sleep, while stage 2 sleep in creased. This increased consolidation of sleep on nef azodone seemed to occur after a possible delay in sleep onset. There is also some indication that in relation to baseline, the duration and density of REM sleep may increase with treatment in the frrst two REMPs and de cline later in the night. These effects did not reach statistical signifIcance. We included two duration measures describing REM episodes. One (REMDUR) reflects the total dura tion of the REM period, including any intervening NREM sleep or wakefulness. This statistic, compared to net REM minutes, reflects whether the REM period is consolidated or interspersed with other sleep stages. In this study, both the duration and net minutes of the frrst and second REM periods included during drug treatment, indicating that nefazodone may increase REM period consolidation. Further, duration and minutes of the third REM period decreased, suggest ing that consolidation of REM sleep may be indepen dent of the duration of the REM period.
Important in this study was the absence of REM suppression, a nnding that differentiates nefazodone from 5-HT reuptake blockers as well as most tricyclic antidepressants and all monoamine oxidase inhibitors (Vogel et al. 1990 ). Unlike fluoxetine, paroxetine, and sertraline, nefazodone did not reduce REM sleep or pro long REM latency. Further, nefazodone did not increase nocturnal wakefulness and stage 1 (light) sleep, effects reported for 5-HT uptake inhibitors. Fluoxetine and paroxetine are 5-HT reuptake inhibitors, as is nefazo done (in doses over 400 mg/day), but they lack nefazo done's effects as a 5-HT2 receptor antagonist.
Interestingly, the sleep effects of nefazodone may differ substantially from those of its analogue, trazo done. Mouret et al. (1988) found that trazodone pro- NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO. 2 longed REM latency and increased slow-wave sleep in endogenous depressed patients, without suppressing total REM sleep. On the other hand, in a study of nonen dogenous depressed outpatients who had insomnia complaints, van Bemmel et al. (1991) found that trazo done suppressed REM sleep but had no effect on deep NREM sleep. Ware et al. (1991) have also reported that trazodone suppresses REM sleep in normal controls. Although both drugs are phenylpiperazine agents, they are structurally distinct. In the present study, nefazo done did not prolong REM latency or suppress REM sleep and had no apparent effect on slow-wave sleep. These very preliminary data suggest that nefazodone and trazodone have different effects on sleep ar chitecture.
Some investigators have suggested that at least for patients with endogenous depression, REM sleep sup pression may be a predictor of antidepressant response (Kupfer et al. 1981; 1987) . Vogel and colleagues have proposed that drug-induced suppression of REM sleep is, in fact, the mechanism of action of most antidepres sant medications. Antidepressant-induced REM suppres sion may occur in both endogenous and nonendogenous depressed patients (Ware et al. 1989) . Furthermore, some antidepressant drugs, such as trirnipramine and nefazodone, do not suppress REM sleep, although they clearly alleviate depression. In an extensive review of drug effects on REM sleep in endogenous depression, Vogel et al. (1990) have shown 22 of 25 effective anti depressants are probable REM sleep suppressors. Trim ipramine, iprindole, and amineptine did not suppress REM sleep. Thus, REM sleep suppression may be a likely mechanism of action in most antidepressants, but clearly is not the sole action of drug response.
Our results support previous studies suggesting that nefazodone has somewhat novel sleep effects. It appears to decrease light sleep as well as arousals from sleep with no decrease in total REM sleep. In fact, REM sleep periods in the frrst half of the night (frrst and sec ond REM periods) may increase, giving way to a mod est decrease in the length of the third REM period. This effect may not have reached statistical signifIcance due to sample size.
Whether the sleep effects of nefazodone are inde pendent of the therapeutic effects of the drug or are re lated to the reduction in depressive symptoms through patient-physician contact cannot be answered by these data. Comparison with studies of other antidepressants would suggest that the effects observed were caused by nefazodone rather than clinical remission alone, par ticularly because REM increased in the frrst two REM periods. Nefazodone also appears to increase REM in normal controls (Ware et al. 1991; Sharpley et al. 1992) , suggesting the REM increases observed in our depressed patients are due to drug effects and not due to therapeutic response per se. Because no placebo con-trol was included in this study, the degree of antidepres sant efficacy cannot be evaluated. However, previous clinical trials suggest that nefazodone is an effective an tidepressant (Feighner et al. 1989; Fontaine et al. 1991) . 
